Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

SUPAIR Spectroscopy: Single-Use Process Analytical Infrared Spectroscopy

Project description

Innovative mid-infrared spectroscopy and bioreactor monitoring

The biologic drug production usually involves the cultivation of mammalian cells in bioreactors. Current on-line monitoring of the bioreactors by mid-infrared spectroscopy systems is expensive, requiring consecutive sterilisations with high water and energy consumption. German IRUBIS developed a single-use silicon attenuated total reflectance (ATR) crystal integrated into a single-use ATR flow cell for read out by a compact Fourier transform infrared spectrometer. It creates a flexible, low-cost, automated system solution and eliminates sterilisation requirements allowing for energy savings. The EU-funded SUPAIR Spectroscopy project will conduct a phase 1 feasibility study to define the technical, market and commercial roadmap to offer a higher-value product.

Objective

The biopharmaceutical industry is poised to reach an impressive market size of more than €300 billion by 2025. The production of biologic drugs is usually performed by cultivating mammalian cells within bioreactors. Those reactors are increasingly being monitored online by means of Process Analytical Technologies (PAT). However state-of-the-art techniques render both sub-optimal product quality and product efficiency. A complete mid-infrared (MIR) spectroscopy system using online Attenuated Total Reflectance (ATR) probes is highly expensive costing around €200,000, €20,000 only for the probes that are not robust enough, requiring consecutive sterilization to be reused (raising water and energy consumption).
IRUBIS GmbH team goal is to make online monitoring of (single-use) bioreactors affordable. IRUBIS innovation comprises a single-use patent-pending silicon ATR crystal integrated in a single-use ATR Flow Cell which is read out by a compact Fourier Transform Infrared (FTIR) Spectrometer. IRUBIS Analytical Technology offers a system that will allow for the first time real-time process control (online) in single-use bioreactors. This means a flexible, highly automated system solution that costs half the price of the competing solutions. Furthermore, it eliminates sterilization requirements allowing for important energy savings.
IRUBIS has been awarded an accelerator program promoted by Merck; Company recent merits also include the Medical valley award (€500,000) and the Exist scholarship (€150,000).
Our business model will be based in two revenue streams: B2B direct sales of developed IRUBIS optical sensors to biopharma companies and sales through partnerships with distributors. The feasibility study we will carry out under this SME Phase 1 project, will define the technical, market and commercial roadmap allowing to offer customers a higher value product.

Programme(s)

Topic(s)

Funding Scheme

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

IRUBIS GMBH
Net EU contribution
€ 50 000,00
Address
BAYERSTRASSE 85A
80335 MUNCHEN
Germany
SME
Yes
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00